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ABSTRACT
Background: Oral bioavailability of gliclazide, a hypoglycemic drug, is hindered by its low 
aqueous solubility. Improvement of solubility will enhance dissolution rate and in turn 
the bioavailability. This research aimed to formulate the solid dispersed gliclazide using 
a novel polyethylene glycol–polyvinyl caprolactam–polyvinyl acetate grafted copolymer 
(Soluplus®) as carrier to enhance in-vitro dissolution and to study drug-carrier physical 
interaction. Method: Final solid dispersion (SDGLC) containing drug:carrier (1:8 w/w) 
was prepared by solvent evaporation after drug-polymer miscibility study. The SDGLC 
powder was characterized by differential scanning calorimetry (DSC), attenuated total 
reflectance infra-red spectroscopy (ATR-IR), powder X-ray diffraction (PXRD), and 
scanning electron microscopy (SEM). SDGLC powder was filled in gelatin capsule after 
flowability and moisture analysis followed by assay, disintegration and in-vitro dissolution 
study. Results: Miscibility study showed negative values of free energy transfer indicating 
spontaneous solubilization of drug with increase in carrier concentration. Absence of 
sharp melting peak in SDGLC was observed by DSC. Reduced peak intensity at specific 
2θ values in PXRD indicates loss of crystallinity in solid dispersion. Interaction to form 
H-bond between gliclazide and Soluplus® was evidenced by ATR-IR. SDGLC filled 
capsule resulted in 20% improved dissolution (approximately 20% higher) in 0.1(N) 
HCl and phosphate buffer pH 7.4 compared to physical mixture (gliclazide-Soluplus®) 
containing capsule. Conclusion: Soluplus® effectively enhanced gliclazide solubility in 
solid dispersed state and SDGLC powder filled capsules could provide pH independent 
and improved in-vitro dissolution for gliclazide.
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INTRODUCTION
Limited aqueous solubility of  active phar-
maceutical ingredients (API) can delay the  
dissolution which may eventually lead to 
poor bioavailability. Various approaches have 
been adopted to address poor dissolution 
issue which include chemical modification of  
drug such as salt formation,1 prodrug for-
mation2 or physical modification of  drug 
such as mechanical micronization,3 micro 
or nano scale particle formation4 and solid 
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dispersion.5 Despite some stability related 
drawbacks such as lack of  adequate scal-
able methods, poor physical and chemi-
cal stability and processing difficulties of  
amorphous materials, solid dispersion is 
one the prevalent approaches practiced for 
pharmaceutical formulation development 
with poor soluble  
API.6-7 Solid dispersed formulation is usu-
ally a binary or ternary system where drug 
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is dispersed in a hydrophilic polymeric carrier such as 
polyvinyl pyrrolidone (PVP K30), poloxamer, poly eth-
ylene glycol, hydroxyl propyl methyl cellulose (HPMC) 
or in the  
form of  solid solution, eutectic mixtures or amorphous 
precipitates.7
Polyethylene glycol–polyvinyl caprolactam– polyvinyl 
acetate grafted copolymer (Soluplus®) is a newer addition 
to the polymeric solubilizer family with some distinct 
features and advantages. It possesses a bifunctional 
character; hence it may act as matrix forming agent 
for solid solution as well as solubilizer for poor soluble 
drug. Soluplus® was observed to be highly capable in 
solubility enhancement of  Biopharmaceutics Classifi-
cation System (BCS) class II and class IV drugs.8 Due 
to hydrophilic and non-ionic nature, its solubility does 
not change with changing pH of  gastro-intestinal tract.9 
With its water solubility and comparatively low glass 
transition temperature (approximately 70°C), Soluplus® 
had been employed in previous studies for different 
method of  solid dispersion preparations such as hot 
melt extrusion for Lafutidine10 or solvent evaporation 
for atorvastatin.11 
Gliclazide (GLC), a second-generation sulphonyl urea 
compound is used to treat type II diabetes mellitus. 
Belonging to BCS class II, GLC has poor solubility but 
high permeability and its oral bioavailability depends on 
its dissolution in the gastrointestinal tract.12 Solid 
dispersion of  GLC was developed by various researchers 
using different carriers such as polyvinyl pyrrolidone, 
Mannitol, polyethylene glycol and so on.12-13 But there 
was no report published on rendering GLC solid 
dispersion using novel polymeric solubilizer such as 
Soluplus®.
The aim of  this study was to formulate a GLC-Soluplus® 
solid dispersed powder and evaluate its solid state 
characteristics. Solid dispersion was prepared by solvent 
evaporation method and the dispersed powder was 
characterized by differential scanning calorimetry (DSC), 
attenuated total reflectance infra-red spectroscopy 
(ATR-IR), powder X-ray diffraction (PXRD), and scanning 
electron microscopy (SEM). Finally, the powder was 
studied for flow ability evaluation followed by capsulation 
and in-vitro dissolution study along with various capsule 
characteristic evaluation.
MATERIALS AND METHODS
Chemicals and Reagents
GLC as white crystalline powder with ‘d50’ value as 40 µ 
(particle size) was generously donated by IKOP Sdn 
Bhd (Malaysia). Soluplus® was obtained as gift sample 
from BASF SE (Germany) in yellowish white free flowing 
powder form. Bovine gelatin capsules (size 1) were 
donated by IKOP Sdn Bhd (Malaysia). Aerosil® R 972 
was obtained as gift sample from Evonik Industries AG 
(Germany). Acetonitrile (HPLC grade) and methanol 
(analytical grade) were purchased from Merck KGaA 
(Germany).
Miscibility Study between Drug and Polymer
Excess amount of  GLC and the solution of  Soluplus® 
(1–15% w/v in water) were sealed in small bottles and 
shaken at 37 ± 0.5°C for 24 h at 500 rpm using incubator 
shaker (New Brunswick Innova 4000, Hauppauge, NY). 
The samples were filtered through a 0.45 μm syringe filter 
and GLC concentration were determined spectropho-
tometrically at 227 nm using an UV-visible spectro-
photometer (Shimadzu 1800, Tokyo, Japan). All the 
measurements were carried out in triplicates. The Gibbs 
equation was used to calculate the free energy transfer 
(ΔG0t) of  GLC from pure water to the aqueous polymeric 
solution as followed:
∆ = −G RT S St S
0
02 303. log( )/
Where, S0/Ss is the ratio of  molar solubility of  GLC in 
aqueous solutions of  carrier to that of  the same medium 
without carrier. R and T are the universal gas constant 
and temperature in Kelvin respectively. 
One to one complex apparent stability constant (Ka) 
was determined as follows:
Ka =Slope / Intercept (1-Slope)
Where, slope and intercept were obtained from the graph 
of  mean GLC concentration in µg/mL vs respective 
Soluplus® concentration (% w/v). 
Preparation of Solid Dispersion
Solid dispersion was prepared by conventional solvent 
evaporation method. Required amount of  GLC was 
dissolved in lowest possible quantity of  ethanol and 
Soluplus® was dispersed in the solution. The mixture 
was then subjected to dry using a rotary vacuum evapo-
rator (BUCHI R 210, Switzerland). The almost dried 
residue was collected from the flask and kept in 
desiccator containing calcium chloride to remove residual 
ethanol. The solid formulation was then pulverized, 
passed through sieve (mesh no: 70) sieve and stored in 
air-tight bag for further studies. GLC: Soluplus® used 
to prepare solid dispersion were 1:1, 1:3, 1:5 and 1:8 w/w.
Saturation Solubility Study
Solid dispersed GLC powder and physical mixture 
(prepared in same ratio as per the solid dispersed powder) 
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containing equivalent amount of  excess GLC were 
added to 10 mL of  distilled water in small vials followed 
by sealing and shaking at 37 ± 0.5°C for 48 h at 500 rpm 
using an incubator shaker. The samples taken were 
analyzed by UV spectrophotometry at 227 nm after 
subsequent dilution. The drug solubility data was 
calculated using a pre-constructed linearity curve. From 
aqueous solubility data GLC: Soluplus® ratio was 
finalized as solid dispersion composition for further 
characterization and capsulation. That finalized solid 
dispersion was abbreviated as SDGLC in further discussion.
Solid State Characterization of GLC-Soluplus® 
Solid Dispersion
Differential Scanning Calorimetry (DSC)
Thermograms of  pure GLC, Soluplus®, physical mixture 
of  GLC: Soluplus® (referred as PMGLC hereafter) and 
SDGLC were derived by a Differential Scanning Calorimeter 
(1-STARe, Mettler Toledo, Columbus, OH). The sample 
(8–10 mg) was enclosed in an aluminium crucible and 
exposed to a thermal range of  50–250°C (10°C/min) 
under a constant nitrogen flow (10–20 mL/min). 
A closed aluminum crucible without sample was used 
as the blank.
Attenuated Total Reflectance Spectroscopy (ATR-IR)
ATR-IR was studied to determine compatibility and 
possible interactions of  GLC with Soluplus® in physical 
mixture and solid dispersed powder. Pure GLC, pure 
Soluplus®, PMGLC and SDGLC sample (50-70 mg) were 
firmly clamped against the ATR diamond crystal with 
force <90 units and scanned over an IR range of  4000-
400 cm-1 with accumulations 15 scans at resolution 
2 cm-1 by an IR spectrometer (Parkin Elmer). The func-
tional groups denoted by IR spectrum were compared 
between all samples and analyzed afterward.
Scanning Electron Microscopy (SEM)
A scanning electron microscope (Evo 50, Carl Zeiss, 
Carl Zeiss Microscopy, Jena, Germany) was employed 
to study the morphology of  pure GLC, PMGLC and 
SDGLC. A small amount of  sample was sprinkled onto 
the sample holder with a double sided carbon tape 
sticking to it. The sample was then coated with gold 
by a table top sputter coater (Leica EM SCD005, Leica 
Microsystems (SEA) Pte. Ltd., Singapore) in order to 
make a thin conductive film. The SEM micrographs, 
captured by the inbuilt software were then compared 
with visual observation.
Powder X-ray Diffractometry (PXRD)
PXRD study was carried out to determine the crystallinity 
of  the solid dispersed powder using an x-ray diffractom-
eter (Rigaku Ultima IV, Japan). The sample powder was 
placed on the PXRD sample holder and scanned from 
0° to 70° with a rate of  5°/min where Cu-K α radiation 
was 30 kV and 15 mA. Diffraction angles (2θ) were 
recorded along with intensity and compared between 
pure GLC, PMGLC and SDGLC.
Pre-Capsulation Studies: Moisture Content and 
Flow Property
The SDGLC and PMGLC powders were tested for moisture 
content by a Halogen Moisture Analyzer (METTLER 
TOLEDO, Canada) before filling into gelatin capsule. 
Before flow property measurement 0.5 wt% of  Aerosil® 
was mixed properly with both PMGLC and SDGLC powder. 
Aerosil® is widely used as a glidant or flow- modifier 
in formulation of  tablet or capsule. Flow property was 
analyzed by determining the flow indicators such as 
Carr index (CI) and Hausner ratio (HR). Bulk density 
(ρBD) and tapped density (ρTD) was measured by a gradu-
ated measuring cylinder and tap densitometer as per the 
method described by Ruzaidi et al.14 Pre-weighed 
samples were poured into the measuring cylinder. 
Poured bulk volume was measured after manual tapping 
of  the cylinder on a flat surface. Tapped volume was 
measured after tapping the cylinder by tap density tester 
(Copley scientific, JV1000) for 500, 750 and 1250 taps. 
Two factor ANOVA was applied to evaluate and 
compare the significance of  CI values. CI and HR were 
calculated using the following equations:
CI TD BD
TD
=
−ρ ρ
ρ
HR TD
BD
=
ρ
Capsulation of the Powder
SDGLC and PMGLC powders (pre-mixed with Aersoil®) 
equivalent to 20 mg of  GLC was filled into bovine 
gelatin capsule of  size 1 using a manual capsule filling 
machine. Theoretically there should be 189 mg of  
powder in each capsule which includes solid dispersed 
or physically mixed GLC with Soluplus® and Aerosil®.
Physicochemical Evaluation of Filled Capsule
Weight Variation, Assay and Disintegration Time
Both types of  the powder filled capsules (PMGLC and 
SDGLC) were subsequently characterized for weight 
variation by weighing randomly 20 capsules using an 
electrical balance. The average weight was calculated 
followed by calculation of  relative standard deviation 
(% RSD) using the average weight. 
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The assay was done to quantify the GLC content in 
capsule. GLC powder equivalent to 20 mg was taken 
from the powder mix collected from randomly selected 
and pre-weighed 20 capsules and dissolved in 20 ml of  
methanol using a magnetic stirrer. The sample was the 
measured for the absorbance at 227 nm using a UV-Vis 
spectrophotometer after filtering and required dilution. 
The percentage drug content was calculated using a 
linearity curve constructed covering the detectable range.
Disintegration tests were performed by a six station 
USP disintegration apparatus (Electro lab ED-2L, 
India) using 0.1 (N) HCl with temperature maintenance 
at 37 ± 2°C. The time taken by the capsules to disinte-
grate completely into the medium were recorded using 
a stopwatch.
In-vitro Dissolution
In-vitro dissolution study was done by a USP type I basket 
type apparatus using two different medium such as 0.1 N 
HCl (pH 1.2) and phosphate buffer pH 7.4 where the 
medium volume was 900 ml at 37 ± 2°C. The samples 
were taken at 15, 30, 60 and 120 min and analyzed by 
high performance liquid chromatographic (HPLC) system 
coupled to UV detector after filtering and required dilu-
tion. The HPLC parameters can be briefly summarized 
as; column: Agilent Zorbax C18 (250×4.6 mm diameter, 
5 µ pore size), elution: isocratic, mobile phase: acetonitrile: 
water (70:30) v/v, detection wavelength: 227 nm, chro-
matographic run time: 7 min, GLC retention time: 4.324 
min. The cumulative percent drug release was calculated 
from the area response derived from the samples and 
reference standard of  GLC and plotted against time in 
minutes. Both type of  powder filled capsules such as 
SDGLC and PMGLC were used to compare the in-vitro 
dissolution study. Therefore, similarity factor (f2) have 
been calculated to compare the dissolution profile of  
SDGLC and PMGLC capsules as well as to compare the 
dissolution of  both capsules with respect to different 
pH. The equation used to calculate f2 is given below.
15
f RT Tt n2
2 0 550 1 1 100= + − −* [{ ( ) * / } * ].£
Where, Rt is GLC dissolution from SDGLC capsule, Tt is 
GLC dissolution from PMGLC capsule and n is number 
of  sampling points (n=4) in the present research.
RESULTS
Miscibility Study between Drug and Polymer 
The results of  miscibility study using Gibbs’ equation 
were expressed in Table 1. The miscibility of  GLC with 
Soluplus® showed a linear relationship with R2 (corre-
lation co-efficient) = 0.9896. With increasing concen-
tration of  Soluplus® the molar solubility of  GLC was 
increased up to 23.10 at 10% w/w Soluplus® concen-
tration. From Gibbs’ energy calculation all the ΔG0t values 
were shown negative. The negative values indicated 
spontaneous solubilization of  drug with the polymer.16 
The Ka value determines the affinity of  the drug towards 
polymer. The higher the Ka value, the better the affinity. 
GLC showed positive and quite high Ka value indicating 
good affinity of  the drug with Soluplus®.
Aqueous Solubility Study and Determination of 
Final GLC-Soluplus® Ratio
Aqueous solubility data of  different solid dispersed 
materials and physical mixtures were described by 
Figure 1. It was observed that aqueous solubility of  
GLC increased in presence of  Soluplus® irrespective of  
physical mixture or solid dispersed powder. However, the 
solid dispersed materials showed better improvement of  
GLC solubility than physical mixture at all drug: carrier 
ratios. With increased ratio of  Soluplus®, GLC solubility 
was increased from 1.32 mg/ml (GLC: Soluplus®; 1:3) 
to 2.36 mg/ml (GLC: Soluplus®; 1:8). Despite the fact 
that the higher the polymer the better the solubility, we 
restricted the carrier amount to 8 gm with respect to 
1 gm of  GLC because higher carrier amount will have 
negative impact of  the feasibility of  final dosage form 
using solid dispersed powder. This GLC: Soluplus® 
(1:8 w/w) ratio was used as final composition for solid 
dispersion (termed as SDGLC hereafter) and used for 
further solid state characterization as capsulation.
Figure 1: Aqueous solubility of solid dispersed GLC powder 
and respective physical mixtures SD1-3: Solid dispersed 
GLC powder with GLC: Soluplus® (1:3 w/w), SD1-5: Solid 
dispersed GLC powder with GLC: Soluplus® (1:5 w/w), SD1-8: 
Solid dispersed GLC powder with GLC: Soluplus® (1:8 w/w), 
PM1-3: Physical mixture of GLC: Soluplus® (1:3 w/w), PM1-5:  
Physical mixture of GLC: Soluplus® (1:5 w/w), PM1-8:  
Physical mixture of GLC: Soluplus® (1:8 w/w).
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nature. Soluplus® showed two broad endothermic 
band at 74.22 and 316°C. PMGLC showed presence of  
GLC peak with a little forward shift. SDGLC thermogram 
showed a broad and small endotherm at 165°C. 
ATR-IR Spectroscopy
The IR spectrum for GLC and Soluplus® was compared 
with the spectrum of  PMGLC and SDGLC with respect 
to the key functional groups. The combined spectra 
for all samples are represented by Figure 3. IR spectra 
of  GLC is characterized by distinct IR peaks at 1707 cm-1 
(absorption of  C=O group), 1162, and 1345 cm-1 
(stretching vibration of  S=O of  sulphonyl urea group).17 
In PMGLC and SDGLC the peaks at 1707 cm
-1 was shifted 
towards little higher frequency at 1725 cm-1. The peak 
at 3269 cm-1 due to NH group belonging to pure GLC 
is shifted to 3462 cm-1 in PMGLC which is further absent 
in SDGLC. Soluplus® spectra is identified by characteristic 
peaks at 3452 cm-1 (O-H stretching), 2927.44 cm-1 
(aromatic C-H stretching), 1732 and 1635 cm-1 (C=O 
stretching). All these peaks of  Soluplus® are present in 
PMGLC however there are little shift of  C=O stretching 
(1635 cm-1) to lower wavelength (1615 cm-1) in SDGLC. 
The presence of  major characteristic peaks of  GLC and 
Soluplus® in PMGLC can be considered as evidence of  
no potential incompatibilities between the drug and 
carrier. The peak shifting from GLC to SDGLC is attributed 
to the desirable physical interaction between drug and 
carrier.
Figure 2: Combined DSC thermogram of Soluplus®, GLC and 
SDGLC.
Figure 3: ATR-IR spectra of Soluplus® (a), GLC (b), PMGLC(c) 
and SDGLC (d).
Figure 4: SEM micrograph of pure GLC (a), PMGLC (b) and 
SDGLC (c).
Solid State Characterization
DSC Analysis
The thermograms obtained from DSC analysis was 
presented by Figure 2. Pure GLC showed a sharp endo-
thermic peak at 171°C clearly indicating its crystalline 
Table 1: Parameters describing miscibility study
Concentration of Soluplus® 
% w/w ΔG0t
1 -24.39
2 -25.75
5 -27.98
10 -29.8
15 -30.36
Slope 0.544
Intercept 0.238
Ka 5.017
Ka: Apparent stability constant 
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Scanning Electron Microscopy (SEM)
The photomicrographs obtained from SEM study 
were presented by Figure 4. Pure GLC was shown to 
be irregular shaped crystal in the photomicrograph of  
pure GLC. In PMGLC, drug crystals were found separately 
as well as adsorbed onto the surface of  Soluplus®. 
However, in SDGLC the drug crystals were shown to be 
adsorbed onto the surface of  Soluplus® in fine particle 
size. Although not very clear but some GLC crystal 
were still visible in SDGLC. The porous surface of  solid 
dispersed granules was also observed. 
Crystallinity Analysis (PXRD)
PXRD has been established as a powerful tool to deter-
mine the crystallinity of  powder material. The results of  
XRD analysis were represented by the derived diffrac-
togram (Figure 5). The crystalline nature of  pure GLC 
Figure 5: X-ray diffractogram of pure GLC (a), PMGLC (b) and 
SDGLC (c).
Table 2: Pre-capsulation flow property and moisture content determination of powders
Capsule type
CI ±
SD (n=3)
Flow property classification 
(USP)
HR ± SD 
(n=3) Flow property classification (USP)
PMGLC 17.67 ± 1.28 16-20; Flow property: Fair 1.21 ± 0.019 1.19-1.25; Flow property: Fair
SDGLC 11.90 ± 1.81 10-15; Flow property: Good 1.14 ±  0.023 1.12-1.18; Flow property: Good
CI: Carr index, HR: Hausner ratio, PMGLC : Physical mixture of GLC:Soluplus® (1:8) w/w, SDGLC : Solid dispersion of 
GLC:Soluplus® (1:8) w/w
Table 3: Physicochemical evaluation of capsules
Type of 
capsule Weight variation Assay Disintegration time
Mean weight(mg) %RSD Mean (%) SD (n=3) Mean (min) SD (n=6)
PMGLC 187.00 0.63 98.99 4.13 12.40 0.58
SDGLC 192.93 1.23 97.52 5.04 14.80 1.03
PMGLC Physical mixture of GLC:Soluplus® (1:8) w/w, SDGLC : Solid dispersion of GLC:Soluplus® 
(1:8) w/w
Table 4: Similarity factor (f2) values between different type of capsules and different type of medium
f2 values
0.1(N) Hcl
Phosphate 
buffer pH 7.4
Between SDGLC 
and PMGLC 36.39 37.35
SDGLC PMGLC
Between 0.1 (N) 
Hcl and phosphate 
buffer pH 7.4 74.47 67.28
PMGLC Physical mixture of GLC:Soluplus® (1:8) w/w, SDGLC : Solid dispersion of GLC:Soluplus® (1:8) w/w
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was characterized by sharp peaks at 2θ of  10.69°, 15.08°, 
17.23°, 18.04°, 22.21°, 25. 47°. The highest height of  
the peak was 3057 cps at 2θ of  10.69°. The results were 
in close agreement with previously published research.18 
In the PMGLC, peaks of  pure GLC at various 2θ angle 
were observed but with reduced intensity, which indi-
cated that the crystallinity of  GLC was maintained in 
the physical mixture. Reduction of  peak intensity might 
attribute to the slight amorphous nature of  GLC gener-
ated during physical mixing of  GLC and Soluplus® to 
prepare sample for XRD. In SDGLC no sharp peak of  
pure GLC was visible indicating complete conversion 
of  crystalline drug to amorphous form. This result is 
in-line with the findings of  DSC analysis. 
Moisture Content and Flow Property Analysis
Excess moisture present in the powder may affect the 
flow ability as well as stability of  the solid dispersion. 
All the powders showed moisture content below 1.3%. 
CI and HR are two established flow indicators as per 
the compendia.19 The resulted CI and HR values (Table 2) 
showed that SDGLC powder possessed better flow 
property than physical mixture. The difference in the 
two flow indicator values were statistically significant. 
This can be due to size uniformity derived after sieving. 
Although the flow ability of  SDGLC powder was not 
“excellent” as per the flow property table19 but the values 
of  CI (11.90 ± 1.81) and HR (1.14 ± 0.023) reached 
near the “excellent” region. 
Physicochemical Analysis of Filled Capsule
Results of  weight variation, disintegration and assay 
tests were presented in Table 3. The experimental evalu-
ation showed low %RSD of  weight between 20 capsules 
(SDGLC: 0.63, PMGLC: 1.22). The weight range of  all 
weighed capsule was 185 to 189 mg and 190 to 193 mg 
for SDGLC and PMGLC powder filled capsule respectively 
and no capsule was beyond the ± 5% level of  their 
average weight. Therefore, the weight variation can be 
considered as acceptable for both type of  capsules.20 
The results of disintegration test showed (Table 3) that 
the time of  complete disintegration for both types of  
capsule were less than 14.8 min. If  the capsule took 
longer time to disintegrate then its bioavailability would 
also be affected. Solubility of  the drug and excipient is 
major contributing factor of  proper disintegration.21 In 
order to facilitate capsule disintegration, various disin-
tegrants can be used such as corn starch, sodium starch 
glycolate etc. However, in this research favourable dis-
integration has been achieved without any disintegrant. 
The assay performed with filled capsules showed 
acceptable results for both type of  capsule (Table 3). 
Mean assay of  3 set of  analysis were 97.52 and 98.99% 
(with respect to 20 mg of  GLC) which is within the 
general acceptable limit which is 95-105% of  the label 
claim. This result ensures that GLC was loaded as solid 
dispersed powder properly.
In-vitro dissolution study was carried out in two different 
mediums; 0.1 (N) HCl (pH 1.2) and phosphate buffer 
(pH 7.4). GLC was reported in literatures to possess 
pH dependant solubility in aqueous medium. In pH 1.2 
it is more soluble than pH than pH 4.5-5. Then with 
increasing pH from 6 to higher, the solubility of  GLC 
is increased.22 In this research, formulation of  GLC was 
either mixed or solid dispersed in Soluplus® which is 
claimed to bear pH independent solubility. A low pH 
(1.2) and a high pH (7.4) dissolution mediums were used 
to determine whether solubility improvement reflects 
into improved dissolution in both medium or not. The 
results of  the in-vitro dissolution study were presented 
by Figure 6. 
The f2 has been calculated (Table 4) to compare the 
dissolution profile of  SDGLC and PMGLC with respect 
to two different pH. In both pH, SDGLC resulted better 
dissolution profile compared to PMGLC
 capsule. In case 
of  SDGLC capsule more than 92% of  drug was dissolved 
in both mediums whereas only more than 78% drug 
has been released from PMGLC. Considering initial time 
points also SDGLC capsule performed better with 50% 
drug release within 30 min compared to PMGLC
 capsule 
with 50% drug release after 40 min. The f2 value was 
Figure 6: In vitro dissolution plot (Time in min vs Cumulative 
percent release) of PMGLC and SDGLC capsules.  
(a) Dissolution in 0.1(N) Hcl, (b) Dissolution in phosphate 
buffer pH 7.4.
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used to compare dissolution profile between two dif-
ferent formulations. Two formulations were considered 
similar if  f2 value lies within 50-100.
15 In our research f2 
value between SDGLC and PMGLC capsules are 36.29 
(0.1 (N) HCl) and 37.35 (phosphate buffer pH 7.4) 
which indicated the dissimilarity between the two 
in-vitro drug dissolution profile.
Comparison of  in-vitro dissolution profile between 
two different dissolution mediums (pH 1.2 and pH 7.4) 
resulted no significance difference in cumulative percent 
release as well as f2 value. Regarding SDGLC capsule within 
1 h in-vitro dissolution was 96.52% in phosphate 
buffer pH 7.4 whereas in 0.1 (N) HCl it was 92.99%. 
Same applied to PMGLC capsule as well. It showed 
dissolution of  78.17% in 0.1 (N) HCl and 81.95% in 
phosphate buffer pH 7.4 indicating almost same rate 
and extent of  dissolution. The f2 values (Table 4) derived 
from the dissolution profile of  both type of  capsules 
in two different mediums are above 50 (SDGLC: 74.47, 
PMGLC: 67.28). This indicated the similarity between 
the dissolution profiles in two different mediums with 
respect to same type of  capsule. 
DISCUSSION
Increase in drug-polymer miscibility with increasing 
polymer concentration was also evidenced by the previous 
work.5 Application of  Gibbs equation mathematically 
supported the observation. Soluplus® has a large number 
of  –OH groups making it hydrophilic polymeric solubilizer 
for poor soluble drug. The formation of  micelle is one 
of  the responsible factors behind increased GLC 
solubility with increase in Soluplus® concentration. 
If  results of  all solid-state characterization studies were 
summarized, a clear understanding of  GLC and Soluplus® 
interaction can be developed. In DSC thermogram of  
SDGLC, sharp melting peak of  GLC was absent. This 
feature was attributed to strong interaction between 
drug and polymer that inhibited crystalline behavior of  
GLC suggesting that the drug was present in amorphous 
form.6 This was further supported by ATR-IR specta. 
The absence of  NH peak of  pure GLC in SDGLC indi-
cated possible interaction between –NH group of  GLC 
and ketone group of  Soluplus® to form amide bond.8 
Additionally the asymmetric stretching vibration band 
of  sulphonyl group in GLC at 1345 cm-1 was shifted to 
higher wavelength at 1371 cm-1 in SDGLC that potentially 
indicated the formation of  H bond with Soluplus®.17 
In SEM micrograph, absence of  distinct GLC crystals 
in SDGLC indicated amorphization of  drug. The porous 
surface seen in SEM micrograph with high hydrophilicity 
of  the career has caused faster drug dissolution.23 In 
PXRD peaks with decreased intensity, featureless scat-
tering peaks or fused peaks with no/less sharp peaks 
were the indications of  reduction or absence of  crystal-
linity. Presence of  no sharp peaks of  pure GLC in SDGLC 
indicated the amorphization of  GLC in Soluplus® solid 
dispersion. GLC has a high melting point (171 ̊ C) which 
is indicative of  strong crystal energy and that is one of  
the factor behind its poor aqueous solubility. Therefore, 
any approach to break the crystal structure and to 
reduce the crystal energy could be beneficial towards 
improvement of  drug solubility. Solid-state dispersion 
has the ability to rupture the crystalline nature of  the 
drug by dispersing it into water soluble carrier molecules 
replacing the drug molecule in the crystal lattice. This 
resulted in a complete or partial loss of  crystallinity and 
thereby significantly improved aqueous solubility of  the 
drug. Soluplus® as a water-soluble polymer has been 
identified to maintain amorphous nature of  the drug 
by inhibiting or retarding crystallization. Therefore the 
formulation of  amorphous solid dispersions with it can 
increase drug dissolution rate and solubility.24-25
The moisture content was little higher in SDGLC powder 
then PMGLC powder which was normal due to higher 
exposure to atmosphere than physical mixture. However, 
the present moisture did not affect the flow ability of  
the powder. Although the flow indicators studied in this 
research (CI and HR) had showed excellent; flow ability 
but flow property is not an intrinsic property of  powder 
mass. It can be changed with type of  measurements, 
handling and storage, moisture content and so on.15 
Therefore, practically acceptable flow property must 
be determined during large scale powder handling. In 
in-vitro dissolution study, improved dissolution profile 
of  SDGLC capsule can be explained by improvement of  
solubility by SDGLC powder. Once the solid dispersed 
powder came in contact with the medium, it started to 
dissolve readily due to very fine or amorphous nature 
of  drug which enhanced the surface area due to reduced 
crystallinity and enhanced the wettability due to the 
presence of  hydrophilic solubilizer.8 Regarding similar 
dissolution profile in two different pH mediums, it can 
be explained that the presence of  Soluplus® or the 
amorphization of  GLC can improve drug solubility in 
both pH and that has been reflected in in-vitro dissolution.
CONCLUSION
The prepared GLC-Soluplus solid dispersed powder 
formulation with drug: polymer ratio (1:8 w/w) has 
exhibited the improved solubility compared to pure 
GLC. Solid state characterization revealed conversion 
of  crystalline drug to amorphous form along with 
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certain degree of  physical interaction. The improved 
solubility has reflected in the improved dissolution for 
solid dispersed GLC powder filled capsules. The flow 
property of  solid dispersed powder was desirable for 
capsule filling. The solid dispersed GLC powder with 
Soluplus® can be used to formulate GLC capsules with 
improved dissolution in different pH. However, the 
stability study with the capsules in proper packaging 
should be carried out before scale-up or further relevant 
action.
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SUMMARY
Gliclazide solid dispersion in Polyethylene glycol–poly-
vinyl caprolactam–polyvinyl acetate grafted copolymer 
(Soluplus®) carrier was prepared by solvent evapora-
tion method. Optimum formulation was developed in 
1:8 weight ratio of  gliclazide: Soluplus®. Developed 
solid dispersed powder was capsulated which resulted 
in improved dissolution in acidic and basic pH medium
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